Statins for acute coronary syndrome

Family Medicine, St Mary's Hospital, McGill University, 377 Rue Jean Brilliant, Montreal, Quebec, Canada, H3T 1M5.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 06/2011; 9(6):CD006870. DOI: 10.1002/14651858.CD006870.pub2
Source: PubMed


Long-term therapy with statins (for at least one year) has been shown to reduce the risk of heart attack, stroke, and all-cause mortality in patients with and without established coronary heart disease. The early period following an acute coronary syndrome is a critical stage of coronary heart disease, with a high risk of recurrent events and death. We aimed to determine if early initiation of statins improves patient-relevant outcomes within the first four months following an acute coronary syndrome. This review is an update of a review previously published in 2011 that included 18 studies, enrolling 14,303 patients. The update of this review did not identify any new studies for inclusion. We did not find a significant risk reduction for all-cause mortality, heart attack, or stroke within the first four months. We had some concerns about risk of bias and imprecision of the results. The risk of unstable angina was reduced by about 25% at four months following acute coronary syndrome. Serious side effects from early treatment with statins were rare (0.1%), and serious muscle toxicity was mostly observed with simvastatin 80 mg.

Download full-text


Available from: Furio Colivicchi, Oct 08, 2015
1 Follower
84 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Bestimmte Arzneistoffe gelten als potenziell ungeeignet für geriatrische Patienten; auf ihren Einsatz sollte möglichst verzichtet werden. Potenziell inadäquate Medikationen (PIM) wurden zu unterschiedlichen PIM-Listen zusammengefasst. 2010 erschien die deutsche PRISCUS-Liste. Ziel der vorliegenden Untersuchung ist die Bewertung der PRISCUS-Liste im Vergleich mit internationalen PIM-Listen. Material und Methoden Basierend auf ausgewählten PIM-Listen (PRISCUS, STOPP/START, Beers) wurde die Medikation von 308 Patienten einer geriatrischen Rehabilitationsklinik auf PIM untersucht. Einschlusskriterium der Patienten war ein Alter von ≥ 65 Jahren. Ergebnisse Bezüglich ermittelter PIM unterlag die PRISCUS-Liste quantitativ den STOPP-Kriterien. Während des Aufenthalts erhielt jeder Patient durchschnittlich 1,2 PIM gemäß STOPP-Kriterien und 0,5 PIM nach der PRISCUS-Liste. Die geringste Anzahl lieferte die Beers-Liste (0,4 PIM). Schlussfolgerung Vom Einsatz der Beers-Liste sollte wegen der fehlenden Anpassung an den deutschen Arzneimittelmarkt abgesehen werden. Eine Anpassung der PRISCUS-Liste um diagnoseabhängige STOPP-Kriterien könnte dazu beitragen, Therapieerfolg und Arzneimitteltherapiesicherheit bei geriatrischen Patienten wesentlich zu verbessern.
    Zeitschrift für Gerontologie + Geriatrie 01/2012; 46(1). DOI:10.1007/s00391-012-0324-4 · 0.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It has repeatedly been shown that statins decrease morbidity and mortality in patients with atherosclerosis, thus supporting their use for the primary and secondary prevention of ischemic heart disease. Different pathological pathways that are triggered in the setting of acute coronary syndrome (ACS), such as endothelial dysfunction, activation of inflammatory and coagulation cascades, and thrombus formation, are known to be inhibited by statins, thereby justifying the use of these agents in patients with ACS. Several recent prospective controlled clinical trials have demonstrated the safety and, in some cases, the efficacy of statins when administered early after ACS. An increasing number of publications have reported, however, that statins may confer a beneficial effect not only in early secondary prevention, but also in the direct treatment of ACS (ie, when statins are administered as first-line treatment in clinically unstable patients). This therapeutic option is supported by the following: numerous experimental studies demonstrating a protective effect of statins under conditions of acute ischemia; analysis of different registries and trials, which has demonstrated a more favourable prognosis for statin-treated patients at the time of acute myocardial ischemia; and small clinical trials reporting a lower periprocedural infarction rate during coronary intervention or lower levels of several prognostic biomarkers, in addition to a lower incidence of cardiovascular events associated with statin therapy. Nevertheless, confirmation of this hypothesis in large prospective controlled clinical trials will be necessary before the implementation of statins as first-line therapy in unstable patients with ACS, irrespective of blood cholesterol levels.
    Experimental and clinical cardiology 12/2012; 17(4):227-236. · 0.76 Impact Factor
  • Source
    Journal of the American College of Cardiology 09/2013; 62(25). DOI:10.1016/j.jacc.2013.08.1626 · 16.50 Impact Factor
Show more